ClinicalTrials.gg
CompletedNCT05398913RIMOFATSCI-1Updated Nov 15, 2022

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

A Phase 1/2 interventional study of Rimonabant in Spinal Cord Injuries, sponsored by Hospital Nacional de Parapléjicos de Toledo. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Hospital Nacional de Parapléjicos de Toledo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled May 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Spinal Cord Injuries with a site in Spain — 12 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Enrollment
51st of 55
8 · median 30
Started
2021
with 7 others
Phase 1/2
7 of 59
2 open now
Registered
39th of 59
by date
Lead sponsor
6 of 59
Hospital Nacional de Parapléjicos de Toledo

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 51st largest by enrollment of the 55 interventional ones that give a count, is one of 8 that started in 2021, is one of 7 in phase 1/2, and was the 39th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Read the detailed description

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Main goal is to test safety of Rimonabant in a specific population (incomplete spinal cord injury).

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Spinal cord injury
  • Walking endurance
  • Incomplete SCI
  • Traumatic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Traumatic spinal cord injury
  • Incomplete lesion (AIS D)
  • Neurological level between C4 and L1
  • Chronic stage (>1 year since injury)
  • Preserved walking ability for at least 5 m (aid allowed)
  • Psychiatric assessment to exclude individuals with high suicide risk
  • Capability to provide
  • For fertile women, possibility to use anti conceptive methods

Exclusion criteria

Exclusion Criteria:

  • Non traumatic spinal cord injury
  • AIS A, B, C or E
  • Neurological level above C4 or below L1
  • Subacute stage (\<1 year since injury)
  • Preserved walking ability for less than 5 m (aid allowed)
  • Pregnancy or breast feeding
  • For fertile women, impossibility to use anti conceptive methods
  • Anticoagulant treatment
  • Hypothyroidism
  • Severe kidney or liver dysfunction
  • Severe depression
  • Fatigue treatment in the last 6 months
  • Impossibility to reach the Hospital
  • Impossibility to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Two pills of placebo will be administered for 5 consecutive days, once per day.

    Drug: Rimonabant

  • Active comparator
    Rimonabant 2.5 mg

    One pill of placebo and one pill of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.

    Drug: Rimonabant

  • Active comparator
    Rimonabant 5 mg

    Two pills of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.

    Drug: Rimonabant

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (safety)

    number of AE

    Time frame: 150 days

  2. 6 min walking test (efficacy)

    6 min walking test (meters and number of stops are reported)

    Time frame: 5 days

  3. Biochemical and urine analysis (safety)

    Number of participants with clinically significant abnormal laboratory tests results

    Time frame: 8 days

  4. ECG (safety)

    Number of participants with clinically significant abnormal ECG readings

    Time frame: 8 days

  5. Beck Depression Inventory (BDI) (safety)

    Range 0-63 (higher values more severe)

    Time frame: 15 days

  6. Hospital Anxiety and Depression Scale (HAD) (safety)

    Range 0-21(higher values more severe)

    Time frame: 15 days

  7. Modified Ashworth Scale (safety)

    Range 0-4 (higher values more severe)

    Time frame: 15 days

  8. Penn Scale (safety)

    Range 0-4 (higher values more severe)

    Time frame: 15 days

Secondary outcomes

  1. 10 m test (efficacy)

    Time to walk 10 m (no stops are allowed)

    Time frame: 5 days and 15 days

  2. 6 min walking test (efficacy)

    6 min walking test (meters and number of stops are reported)

    Time frame: 15 days

  3. Borg Scale (efficacy)

    Borg Scale punctuation after 6 min waking test. Range 0-10.

    Time frame: 5 days and 15 days

  4. WISCI II (efficacy)

    Range 0-20 (higher values less severe)

    Time frame: 5 and 15 days

  5. Motor Score (efficacy)

    Motor Score (ISNCSCI). Range 0-20 (higher values less severe)

    Time frame: 8 days

  6. Fatigue Severity Scale (FSS) (Efficacy)

    FSS puntuación. Range 0-7 (higher values more severe)

    Time frame: 5 and 15 days

  7. European Quality of Life -5 Dimensions (EQ-5D) (efficacy)

    EQ-5D questionnaires have 5 dimensions: "Mobility", "Human Autonomy," "Current Activities", "Pain / Discomfort", "Anxiety / Depression" and all dimensions are described by 3 problem levels corresponding to patient response choices (higher values worst). A quality-of-life score is obtained according to the answers to the questionnaires (algorithm to calculate the score in euroqol.org). The maximum score is 1 that indicates excellent quality of life (range for Spanish version 0.5-1).

    Time frame: 8 days

  8. Patient global impression of changes (PGIC) (efficacy)

    PGIG score. Range 1-7 (higher values indicate worsening)

    Time frame: 5 and 15 days

  9. Pain numeric rating scale

    Range 0-10 (higher values more severe)

    Time frame: 8 days

  10. Health state visual analogically scale

    Range 0-100 mm (higher values indicate higher health state )

    Time frame: 8 days

07

Study locations

1 site
  • Hospital Nacional de Paraplejicos
    Toledo, 45004, Spain
08

References and documents

Individual participant data

Plan to share: No — Upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2022, 12 months.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
Jun 1, 2022
StartActual
May 12, 2021
Primary completionActual
Jun 7, 2022
CompletionActual
Jun 7, 2022
Last update
Nov 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05398913
Lead sponsor
Hospital Nacional de Parapléjicos de Toledo
Responsible party
Antonio Oliviero (Principal Investigator, Hospital Nacional de Parapléjicos de Toledo) — Principal investigator
First posted
Jun 1, 2022
Start date
May 12, 2021
Primary completion
Jun 7, 2022
Completion
Jun 7, 2022
Last update
Nov 15, 2022

Study contacts

Antonio Oliviero, MD, PhD
principal investigator · Hospital Nacional de Parapléjicos

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion